Citalopram improves metabolic risk factors among high hostile adults: Results of a placebo-controlled intervention.

Thomas W. Kamarck  
*University of Pittsburgh - Main Campus*, tkam@pitt.edu

Matthew F. Muldoon  
*University of Pittsburgh - Main Campus*

Stephen B. Manuck  
*University of Pittsburgh - Main Campus*

Roger F. Haskett  
*University of Pittsburgh - Main Campus*

JeeWon Cheong  
*University of Pittsburgh - Main Campus*

See next page for additional authors

Follow this and additional works at: [https://digitalcommons.usm.maine.edu/psychology](https://digitalcommons.usm.maine.edu/psychology)

Part of the Psychology Commons

**Recommended Citation**

This Article is brought to you for free and open access by the Psychology at USM Digital Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of USM Digital Commons. For more information, please contact jessica.c.hovey@maine.edu.
Citalopram Improves Metabolic Risk Factors Among High Hostile Adults: Results of a Placebo-Controlled Intervention

Thomas W. Kamarck\textsuperscript{a,\,*}, Matthew F. Muldoon\textsuperscript{b}, Stephen B. Manuck\textsuperscript{c}, Roger F. Haskett\textsuperscript{d}, JeeWon Cheong\textsuperscript{e}, Janine D. Flory\textsuperscript{f}, Elizabeth Vella\textsuperscript{g}

\textsuperscript{a} Department of Psychology, University of Pittsburgh, 4403 Sennott Square, 210 S. Bouquet St., Pittsburgh, PA 15260
\textsuperscript{b} Department of Medicine, University of Pittsburgh, 506 Old Engineering Hall, 3942 O’Hara Street, Pittsburgh, PA 15260
\textsuperscript{c} Department of Psychology, University of Pittsburgh, 501 Old Engineering Hall, 3942 O’Hara Street, Pittsburgh, PA 15260
\textsuperscript{d} Department of Psychiatry, University of Pittsburgh, 230 Thomas Detre Hall, 3811 O’Hara St., Pittsburgh, PA 15260
\textsuperscript{e} Department of Psychology, University of Pittsburgh, 4121 Sennott Square, 210 S. Bouquet Street, Pittsburgh, PA 15260
\textsuperscript{f} Department of Psychology, NSB D312, Queens College, City University of New York, 65-30 Kissena Blvd., Flushing, NY 11367
\textsuperscript{g} Department of Psychology, University of Southern Maine, 514 Science Building, 96 Falmouth Street, Portland, ME 04104

\*Corresponding author. Tel.: 00-412 624-2080; fax: 412 624-2205. Email address: tkam@pitt.edu (T.W. Kamarck).

Running Title: Citalopram, hostility, and metabolic risk
Summary

Hostility is associated with a number of metabolic risk factors for cardiovascular disease, including waist-hip ratio, glucose, and triglycerides. Along with hostility, many of these measures have also been shown to be associated with reduced central serotonergic function. We have previously reported that a citalopram intervention was successful in reducing hostility by self-report assessment (Kamarck, et al., 2009). Here we examine the effects of this serotonergic intervention on metabolic risk factors. 159 healthy adults with elevated hostility scores were randomized to citalopram or placebo for a 2-month period. Citalopram was associated with favorable changes in metabolic risk factors, including waist circumference \((p = .003)\), glucose \((p=.02)\), HDL cholesterol \((p= .04)\), triglycerides \((p=.03)\), and diastolic blood pressure by automated assessment . \((p = .0021)\). The effect on blood glucose was significantly mediated by treatment-related changes in hostility \((p < .05)\), and all of these metabolic changes were significantly mediated by treatment-related changes in body mass index (in most cases, \(p < .01)\). Results suggest that the association between hostility and metabolic risk factors may be driven, in part, by a direct effect of hostility on metabolic risk. Mechanisms accounting for these associations remain to be explored.

Keywords: hostility; citalopram; metabolic syndrome; randomized clinical trial; ssri; glucose.
1. Introduction

A large body of evidence suggests that otherwise healthy individuals who have high scores on measures of dispositional hostility may be at increased risk for developing coronary heart disease and all-cause mortality (Everson-Rose & Lewis, 2005; Miller, Smith, Turner, Guijarro, & Hallet, 1996). Hostility appears to be important not only by virtue of its independent associations with CHD and mortality, but also because of its well-documented links with other behavioral and biological risk factors for cardiovascular disease. A recent meta-analysis of 27 relevant reports, for example, has shown that hostility, as assessed by the widely used Cook Medley scale (Cook & Medley, 1954), is reliably associated with metabolic risk factors, including waist-hip ratio, glucose and insulin resistance, lipid ratios, and triglycerides (Bunde & Suls, 2006). Each of these factors is an important component of the metabolic syndrome. Such findings highlight the importance of hostility, not only as a precursor of CHD, but as a marker of risk factor covariation as well.

One of the potential mechanisms linking hostility with metabolic risk factors involves variations in central serotonergic activity. Individual differences in central serotonergic activity are commonly indexed by CSF concentrations of serotonergic principal metabolites, or by neuroendocrine (e.g., prolactin) responses to acute administration of a serotonin agonist. Using such measures, reduced central serotonergic function has been shown to be associated with aggression in primates (Botchin, Kaplan, Manuck, & Mann, 1993; Higley, King, et al., 1996; Higley, Mehlman, et al., 1996) and with measures of hostility in
humans, especially among men (Cleare & Bond, 1997; Coccaro, 1997; Manuck, et al., 1998). Recent evidence also suggests that reduced central serotonergic function may be associated with an increased prevalence of the metabolic syndrome in community samples of human volunteers, as assessed by NCEP and IDF criteria (Muldoon, et al., 2006; Muldoon, et al., 2007). Thus, observed associations between hostility and metabolic risk factors may be accounted for by common neurobiological determinants.

Each of the associations described above is drawn from correlational studies. A complementary, experimental approach would allow us to determine if these observed associations are causal in nature. A small experimental literature has suggested that fluoxetine, a selective serotonergic reuptake inhibitor (SSRI) that enhances synaptic availability of serotonin, may also be associated with short term improvements in metabolic function in small samples of diabetic, impaired glucose tolerant, or obese individuals (Breum, Bjerre, Bak, Jacobsen, & Astrup, 1995; Daubresse, et al., 1996; Gray, Fujioka, Devine, & Bray, 1992; Maheux, Ducros, Bourque, Garon, & Chiasson, 1997; O'Kane, Wiles, & Wales, 1994; Potter van Loon, et al., 1992). We took advantage of a larger placebo-controlled SSRI intervention study to examine the possible impact of hostility changes on metabolic risk factors, and the possible role of serotonergic function in driving the relationship between hostility and metabolic risk.

The STAHR (Stress Treatment and Health Risk) study was a placebo-controlled study designed to examine the effects of citalopram on hostility and other cardiovascular risk factors in high hostile healthy adults. Published results
from this study demonstrated significant drug intervention effects on hostile affect and state anger (Kamarck, et al., 2009). In the current report, we examine the effects of citalopram on metabolic risk factors that have been previously linked with hostility, and we explore the potential role of hostility changes in accounting for any observed drug-related changes in metabolic function.

2. Methods

2.1 Participants

We recruited healthy middle aged adults (ages 30-50) with elevated scores on two standard measures of hostility (see below). Exclusionary criteria included history of CVD or other chronic medical conditions (e.g., diabetes), use of medication for cholesterol or high blood pressure (or use of BP medications within the past year), and use of other medications with autonomic effects. Those with fasting blood glucose over 140 mg/ML or blood pressure > 160/100 mmHg were also excluded and were referred immediately for treatment. All of these criteria were designed to reduce the confounding effects of concurrent medication or treatments on metabolic risk.

We excluded those with current Axis I DSM-IV diagnoses, those with excessive alcohol use (> 14 drinks/week or > 2 binges per week), current use of street drugs by self report, or positive urine drug screens, those on any pre-existing psychotropic medications, and those who had taken SSRIs within the past 2 months. To reduce any potential teratogenic risk of the drugs, we also excluded pregnant women (positive pregnancy test), those who were planning to become pregnant, and premenopausal women unwilling to commit to use of a
double barrier contraceptive method during the course of their participation in the study (Kamarck, et al., 2009).

2.2. Overall procedure

Mass mailings with self-addressed return postcards were sent to residents of Allegheny County, Pennsylvania, targeting the age range of interest. Telephone screening interviews were conducted with potential participants who returned the postcard forms. Potential participants were administered a screening instrument by phone which included items from the Cook-Medley and the Buss-Durkee hostility inventories (Barefoot, Dodge, Peterson, Dahlstrom, & Williams, 1989; Buss & Durkee, 1957; Cook & Medley, 1954) and those in the top tertile on both of these instruments were selected, based upon a normative sample. Interested individuals who passed all telephone screening criteria were invited to participate in a laboratory screening session (Visit 1), during which they provided written informed consent followed by administration of a more detailed medical history interview (including anthropometric measures and self-reported smoking history), a portion of the Structured Clinical Interview for DSM-IV (SCID; (First, Spitzer, Gibbon, & Williams, 2002)) to rule out current Axis I diagnosis (see above), a clinic blood pressure screening and finger stick for blood glucose screen, a urine drug screen (to rule out current use of street drugs including cocaine, opiates, and amphetamine), a urine pregnancy test, and several additional questionnaires.

229 individuals enrolled in the study. These participants attended 5 additional “pre-treatment visits” (Visits 2-6) over a 1-1/2 month period (range of
Citalopram, hostility, and metabolic risk

17-108 days. Additional risk factor information was assessed during Visit 2, Visit 3 involved a series of laboratory stressors (not reported here), and Visits 4-6 involved training and feedback for self-report field diary assessments (not reported here). Other questionnaires and interviews were also administered during these pre-treatment visits.

Following the pre-treatment period, subjects were scheduled for an appointment in the medication clinic (Visit 7). They were administered a second informed consent procedure by the study psychiatrist (RFH) during which risks and side effects associated with the study medication were described in greater detail. A urine pregnancy test was re-administered to eligible participants and acceptable methods of contraception were discussed. Participants who remained eligible and interested were randomized to drug or placebo intervention, using a computer generated randomization list. Randomization was performed by the Investigational Drug Service in the School of Pharmacy at the University of Pittsburgh; investigators, research staff and participants were blinded as to condition assignment. At the end of Visit 7, participants were accompanied to the pharmacy facility where they were provided with their drug/placebo bottles. Randomization was implemented by pharmacy workers using information received by the IDS. Drug/placebo administration use was initiated immediately following this visit. 69 subjects were dropped during pre-treatment assessment or prior to randomization (for example, due to schedule conflicts or eligibility concerns), leaving 160 randomized subjects.
The target sample size of 160 was based upon power analyses that drew upon published results; in this study, 81 subjects were randomized to drug and 79 were randomized to placebo. Data for one of these subjects were destroyed by request, leaving us with 159 randomized subjects.

Visit 7 and three additional “treatment titration” visits (Visit 8-10) were completed over a 1-1/2 month period (range of 39-61 days). During each of these visits, each approximately 30 mins in duration, participants met individually with a clinical research nurse. Pill counts were conducted, side effects were discussed, and the new drug dosage for the following visit was determined. A “fixed flexible” dosage range was prescribed: All subjects in the active intervention and placebo conditions were started on a 10 mg (one pill) dose. Those without significant side effects were advised to incrementally increase the dose at each visit up to a maximum of 40 mg (4 pills) by the end of Visit 10. A final medication review visit (Visit 11) was scheduled 2 weeks after the final dose was prescribed during which the “fixed treatment” period began.

During the five “fixed treatment” visits (Visit 11-15 over the next month, range of 9-104 days), most of the pre-treatment measures were readministered once. During this period, participants also underwent three blood draws for assessment of citalopram blood concentrations (not examined here). Following Visit 15, participants underwent a two-week withdrawal period, during which pill dosage was gradually reduced. Visit 16 was a debriefing visit scheduled following the withdrawal period; participants met with investigators in the study (RFH, TWK) to discuss their reactions to the pills and to the study procedures.
Consulting a confidential envelope provided on each participant by the Investigational Drug Service, the PI (TWK) debriefed the participants as to their condition assignment at this time. If they expressed interest, participants were referred for further psychological or pharmacologic treatment.

Data collection for this study spanned a 49-month period, from January 2002- March 2006. The study was conducted in compliance with the University of Pittsburgh Institutional Review Board.

87 % ( n = 139) of randomized participants completed the intervention and the end-of-treatment assessments; 72 of these were in the drug condition, and 67 were in the placebo group. See Figure 1, Recruitment Flowchart. All analyses were conducted on the randomized sample of 159, using the intention-to-treat principle, and missing data were imputed using maximum likelihood methods.

2.3. Hostility measures

A series of self-report measures of hostility were administered, including the Cook-Medley Hostility Scale (CMHS) (Cook & Medley, 1954), the Spielberger State-Trait Anger Expression Inventory (STAXI)(Spielberger, 1988), the Buss Durkee Hostility Inventory (BDHI) (Buss & Durkee, 1957), and the Buss Perry Aggression Questionnaire (BPAQ) (Buss & Perry, 1992). These self-report questionnaires assess multiple aspects of hostility, and each was administered twice, during the pretreatment period and during the fixed treatment period at the end of the study.

When we subjected subscale scores from these measures to factor analysis, we derived a similar three-factor solution for each of the two
assessment points, with the derived factors, in each case, representing measures of hostile cognition, hostile affect, and hostile behavior, respectively. An aggregate measure of trait Hostile Affect was derived by combining scores from the BPAQ Anger subscale, the STAXI Trait Anger and Anger Control (negative loading) subscales, and the BDHI Indirect and Irritability subscales; a trait Hostile Behavior score was derived from the BPAQ Verbal Aggression and Physical Aggression subscales along with the BDHI Assault, Verbal, and Negativism subscales; and trait Hostile Cognition was measured based upon scores from the BPAQ Hostility subscale, the BDHI Resentment, Suspicion, and Guilt subcales, the CMHI, and the STAXI Anger-In scale.\(^3\) Our primary concern in this report involved the Hostile Affect measure, since this was the factor that we showed to be associated with significant citalopram intervention effects (Kamarck, et al., 2009).

Other psychosocial characteristics were also assessed in this study but are not examined in this present report, including measures of depressive symptoms, impulsivity, and perceived social support (Kamarck, et al., 2009).

2.4. Adherence measure

A MEMS (Medication Event Monitoring System) cap (ARPEX/AARDEX Union City, CA) was assigned to each participant at the start of the treatment titration period. This is a prescription drug bottle cap equipped with an electronic chip that is activated with each cap closing, used as a measure of medication adherence. Adherence was assessed as the proportion of intervention days
during which the bottle cap was opened and closed one or more times outside of the clinic visits.

2.5. Side effects measure

At each of the treatment visits (Visit 8-11), participants were administered a 23-item questionnaire (Somatic Symptom Scale, SSS) inquiring about current physical symptoms potentially relevant to the use of citalopram (e.g., dizziness, nervousness, dry mouth). Number of symptoms endorsed by each participant was averaged across sessions; scores were log transformed to reduce skewness.

2.6. Metabolic risk factors

Metabolic risk factors were assessed on two occasions, once at pre-test (Visit 2), and once during the fixed treatment period (Visit 11). For each of these early morning visits, participants were asked to abstain from food and caffeine for 12 hours. Based upon the five criteria of the National Cholesterol Education Program (NCEP) for defining metabolic syndrome, the major dependent measures of interest included waist circumference, fasting glucose, triglycerides, HDL cholesterol, and resting blood pressure. We also assessed body mass index and fasting plasma insulin. Assessment procedures for each of these measures are described below.

2.6.1. Anthropometric measures

Subjects were asked to remove their shoes and all items from their pockets. Height was measured using a standard wall unit, and weight was assessed using a digital scale. Waist circumference was assessed at the level of the umbilicus during mid-respiration, to the nearest half-centimeter. Weight data
were complete at baseline, but follow-up weight data were missing for 22 subjects; 16 were dropouts, and data from 6 additional subjects were missing due to a data collection error. Waist circumference measures were added to the protocol for baseline and follow-up 8 months after the data collection began; therefore, baseline waist data were missing for 17 randomized subjects; 9 of these (including 3 dropouts) were also missing the waist circumference data at follow-up.

2.6.2. Lipid and glucose assays

Following blood draw, serum samples were separated and stored (-70 degrees centigrade). Determinations of serum total cholesterol, high-density lipoprotein cholesterol, and triglycerides were performed by the Heinz Nutrition Laboratory, Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, which has met the criteria of the Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program since 1982. Fasting serum glucose was oxidized to form gluconate and hydrogen peroxide, then reacted with dye precursors catalyzed by peroxidase, which were detected with standard colorimetry at 540 nm. Triglyceride measures were log transformed to correct for skewness, and HDL cholesterol values were dropped for one participant whose baseline measures (baseline HDL of 102) were more than 4 standard deviations from the mean.
2.6.3. Blood pressure

Resting blood pressure was assessed by standard manual sphygmomanometry in the medical assessment office (Visit 1), and by use of an automated device while sitting at rest in the laboratory (Visit 3).

2.6.3.1. Standard manual sphygmomanometry

Subjects were seated for at least 5 minutes prior to their standard blood pressure assessments. Following guidelines from the American Heart Association (Perloff, et al., 1993), 3 seated manual blood pressure readings were taken, at 2 minute intervals, by a trained research nurse, using a standard mercury sphygmomanometer (Vital Signs Model 63154, Country Technology, Gays Mills, WI). The average of the last 2 readings was used.

2.6.3.2. Automated blood pressure assessment

During a larger psychophysiological assessment protocol, five measures of resting blood pressure were recorded from an automatic auscultatory device (Accutracker DX; Sun Tech Medical Inc., Morrisville, NC) during each of five 6-minute baseline epochs (total of 25 assessments for each person). These measures were averaged to obtain estimates of resting cardiovascular functioning, estimates that, by virtue of the number of readings involved were assumed to be more reliable and representative than those assessed using standard manual sphygmomanometry.
2.7. Health behaviors

To help us examine behavioral contributions to any observed changes in weight or metabolic risk, we collected measures of diet, physical activity, and alcohol consumption, as described below.

2.7.1. Dietary recall

Trained interviewers performed two 24-hour dietary recall interviews during the pre-testing interval (Visits 2-6), and again during the fixed treatment interval (Visits 11-15), using the Nutrition Data System for Research (NDSR) software developed by the Nutrition Coordinating Center (NCC) at the University of Minnesota (Sievert, Schakel, & Buzzard, 1989). Measures of total 24-hour caloric consumption were calculated from each interview and averaged within each period (pre-test and fixed treatment). Participants who were missing one or more interviews were not scored.

2.7.2. Physical activity

Subjects were equipped with a pedometer (AE120 pedometer, Accusplit, Inc., San Jose, CA) which they were instructed to wear at the waist on the dominant hip throughout the waking day for a 7 day period, during pre-testing (Visit 2) and again during the fixed treatment period (Visit 11). Step counts were calculated for each day and averaged within each period (pre-test and fixed treatment). Subjects were instructed to record the times and occasions during which the monitor was not worn during the monitoring period; when these periods involved physical activity (such as swimming or biking), step counts were
corrected based upon the estimated metabolic expenditure associated with that activity, and converted to step equivalent units (steps per minute).

2.7.3. Alcohol consumption

Alcohol consumption was assessed during pre-testing (Visit 2) and again during the fixed treatment period (Visit 11) using self-report estimates of wine, beer, and liquor consumption converted to daily grams of alcohol (quantity-frequency method) (Garg, Wagener, & Madans, 1993). Pre-testing assessments were based upon an unspecified time frame (“How often do you…”) and fixed treatment period estimates were based upon the past month (“During the past month, how often have you…”).

2.8. Data analysis

SAS Proc Mixed, which employs Maximum Likelihood estimation, was used to calculate the effects of condition assignment (placebo vs. drug), time (pre-treatment vs. fixed treatment) and their interaction on each of the measures of metabolic risk. When such procedures are used to model the changes in a dependent variable over time, missing data points for such a variable are imputed without the use of list wise deletion, allowing for a fuller utilization of existing data. To verify that any missing data would not change the results, analyses were run using all randomized participants ($n = 159$, intention-to-treat model) and, again, using only those who completed the intervention ($n = 139$). Because the outcome of these two approaches did not differ, we present only the intention-to-treat model results here.
We have previously shown that this citalopram intervention was associated with significant changes in hostile affect (Kamarck, et al., 2009). In order to examine whether the observed effects of citalopram on metabolic risk might be mediated by changes in hostility, we re-ran each of the condition-by-time effects on metabolic risk with pre- and post- measures of hostile affect as a time varying covariate. We tested the significance of such potential mediation using MacKinnon’s Assymetrical Confidence Interval method with the program PRODCLIN (MacKinnon, 2008; MacKinnon, Fritz, Williams, & Lockwood, 2007). In this method, the indirect effect of a mediating variable is assessed as the cross-product of two regression coefficients, one linking the explanatory variable and the mediator (in this case, the regression coefficient associated with the condition-by-time interaction effect on hostility), and the other linking the mediator and the dependent variable (in this case, the regression coefficient describing the association between hostility changes and metabolic changes over the course of the intervention). Because a distribution of a product of two normally distributed variables may not itself be normally distributed, PRODCLIN calculates assymetric confidence intervals for these cross-product terms, based upon the calculated regression coefficients and their respective standard errors.

3. Results

3.1. Baseline sample characteristics

Participants randomized to each of the two conditions did not differ with respect to age, sex, race, education or income. Mean baseline scores were 25.8 (sd=8.5, n=158) for the Cook-Medley Hostility Scale (range=0-50), and 82.8
Citalopram, hostility, and metabolic risk

(sd=16.5, n=158) for the Buss-Perry Aggression Questionnaire (range= 29-145) (no condition differences, see (Kamarck, et al., 2009).

Baseline metabolic risk factors, along with baseline measures of body mass index and insulin are presented, by sex and condition, in Table 1. There were significant sex differences in baseline waist circumference (F (1, 139) = 4.59, p = .03), HDL cholesterol (F (1, 157) = 38.19, p < .0001) and blood pressure (SBP for manual readings, F (1, 158) = 6.82, p=.0099; SBP and DBP for laboratory readings, F (1, 154) = 20.53, p < .0001; F (1,154) = 10.90, p = .0012, respectively). There were no significant condition or sex-by-condition interaction effects for any of these variables.

3.2. Dose, adherence, and symptom reports

Among completers (n = 139), 90 % of those in the drug intervention group (65/72) and 88 % of those in the placebo control condition (59/67) successfully transitioned to the maximum pill dose (40 mg or 4 pills daily) by the end of the treatment titration period. The proportion of those taking the maximum pill dose did not differ by condition (Fisher’s exact test p = .79).

Among completers, the average rate of adherence (proportion of days in the study during which the MEMS bottle was opened one or more times, correcting for clinic visits) was 89 % (range= 39 %-100 %, with 82 % of the sample demonstrating adherence on 80 % or more of the days). There were no main effects of condition on rates of adherence (p = .48). (Kamarck, et al., 2009). There were also no condition differences in somatic symptoms reported during treatment (p = .4) (Kamarck, et al., 2009).
3.3 Drug-related changes in metabolic risk factors

The citalopram intervention was associated with favorable changes in metabolic risk factors, including waist circumference (condition by time (CxT) interaction $F(1, 123) = 9.17, p = .003$), glucose ($F(1, 141) = 5.65, p = .02$), HDL cholesterol ($F(1, 140) = 4.28, p = .04$), and triglycerides ($F(1, 141) = 5.03, p = .03$). In each case, the active drug group showed significant favorable changes over time and the placebo group did not (for waist circumference, -.94 cm, $p = .005$ for active drug group, +.52 cm, n.s for controls; for glucose, -2.4 mg/dl, $p = .03$ in active drug group, +1.4 mg/dl, n.s. in controls; for HDL, +2.2 mg/dl, $p = .008$ in active drug group, -.25 mg/dl, n.s. in controls; for triglycerides, -22.3 mmol/L, $p = .03$ in active drug group, + 5.8 mmol/L, n.s. in controls). See Figure 1 for effect sizes by condition.

There were no significant condition-by-time effects on clinic blood pressure ($F(1, 141) = 1.68 (p = .20)$ for SBP and $1.17 (p = .28)$ for DBP), however, there was a marginally significant condition-by-time interaction on laboratory SBP ($F(1, 139) = 3.76, (p = .05)$ (mean change in active drug group, -1.7 mmHg, $p = .03$, in controls, .68 mmHg, n.s.) and a significant condition-by-time interaction on laboratory DBP ($F(1, 139) = 9.83 (p = .0021)$ as assessed using automated readings (mean change in active drug group, -1.8 mmHg, $p = .0004$, in controls, .43 mmHg, n.s.) (see Figure 1).

3.4. Hostility and weight as mediators

Hostile Affect changes over the course of the intervention were significantly associated with reductions in blood glucose ($F(1, 132) = 8.14$
Moreover, the inclusion of Hostile Affect as a time-varying covariate reduced the magnitude of the time-by-condition interaction effect on blood glucose to marginal significance \( (p = .05, \text{mean change in active drug group, -1.0 mg/dL, } p = .43) \). Hostile Affect changes were unrelated to any of the other metabolic risk factors over the course of the intervention. Using the Assymetric Confidence Limit (ACL) method, we calculated a 95\% confidence range for the indirect or mediating effect of hostility on blood glucose of 1.26- -.06, an effect, in other words, which was statistically significant \( (p < .05) \).

Citalopram was associated with a small but significant changes in body mass in this study \( (CxT F (1, 135) = 12.68, p = .0005) \). Even after three outliers were removed from the sample\(^2\), these significant drug effects remained \( (C x T F (1, 132) = 9.72, p = .002) \) (mean changes in active drug group -.26 k/m\(^2\), \( p = .0027 \), in controls, +.13 k/m\(^2\), n.s.).

We examined whether the changes in metabolic risk we observed might have been mediated by these drug-related weight changes. When we included BMI as a time-varying covariate in the models described above (using conservative models in which the three outliers were removed), the relationship between BMI change and risk factor change was significant in each case (for waist, \( F (1, 123) = 548, p < .0001 \); for glucose, \( F (1, 131) = 4.28, p < .0001 \); for HDL, \( F (1, 130) = -3.71, p = .0003 \); for triglycerides, \( F (1, 131) = 4.41, p < .0001 \); and for laboratory DBP, \( F (1, 128) = 8.4, p = .004 \)). Only two of the five condition-by-time interactions (for glucose and DBP) remained significant. Moreover, all of
the mediation effects were significant by ACL criteria (p < .05 for laboratory SBP, all other effects p < .01).

We examined whether the mediating effects of hostility on drug-related glucose change were independent of the mediating effects of weight. When we included both hostile affect and BMI as time varying covariates in the model, both of these variables continued to be associated with changes in blood glucose (p = .03 for hostile affect and p = .001 for weight), and the mediating effects of hostility remained significant by ACL criteria (p < .05).

3.5. Drug-related changes in health behaviors

We explored the behavioral factors that might have accounted for hostility-related or drug-related weight loss. No significant intervention effects were observed on diet, as assessed by the 24 hour dietary recall measure (for our measure of total caloric intake, time-by-condition $F (1, 130) = 1.16, \text{n.s.}$), on physical activity, as assessed by pedometry (for our corrected step count measure, time by condition $F((1, 131) = .68, \text{n.s.}$), or on quantity of alcohol consumed among drinkers, as assessed by self-report ($F (1, 130) = .07, \text{n.s.}$).

We examined whether any of the observed effects of citalopram on metabolic risk were moderated by gender. When we tested such moderation effects in the models described above, none of the 3-way gender-by-condition-by-time interaction effects were significant, suggesting that, with respect to the effects of citalopram on metabolic risk factors, men and women responded in a similar manner.
4. Discussion

Our results show that in high hostile healthy adults, citalopram caused small but significant beneficial changes in all of the five NCEP components of the metabolic syndrome, including waist circumference, glucose, HDL cholesterol, triglycerides, and, by some measures, blood pressure. Previous studies in smaller samples of diabetic, obese, or metabolically impaired individuals have shown similar salutary effects of short term SSRI administration on metabolic risk. This study differs from previous work in that it involves a larger sample, and one that was preselected with respect to hostility rather than preexisting obesity or metabolic abnormalities.

Moreover, our results suggest that drug-related changes in affective hostility may partially mediate the effects of citalopram on reductions in blood glucose, the central feature of the metabolic syndrome. Previous correlational results have supported an association between hostility and metabolic risk but they have not permitted us to explore the direction of effects or the mechanisms potentially explaining these associations. In this study, the use of an experimental manipulation tested the extent to which hostility drives some of the previously observed associations with metabolic risk. Drug-related reductions in blood glucose seemed to be driven, in part, by changes in affective hostility, whereas other drug-related changes in metabolic syndrome components were not.

We were unable to discern any behavioral mechanisms accounting for the apparent influence of hostility changes on blood glucose, insofar as there were
no detectable effects of the intervention on diet, activity, or alcohol consumption in this study. Other plausible mechanisms not examined here include possible modulating effects of hostility reduction on sympathetic nervous system or HPA axis pathways: Previous corelational research links hostility with increased sympathoadrenal and HPA axis activity (Pope & Smith, 1991; Suarez, Kuhn, Schanberg, Williams, & AZimmermann, 1998); circulating epinephrine and cortisol, in turn, may enhance glycogenolysis, gluconeogenesis (Tonelli, Kishore, Lee, & Hawkins, 2005; Vicini, Avogaro, Spilker, Gallo, & Cobelli, 2002), and lypolysis and the production of nonesterified fatty acids (Bray, 1967; Orth & Williams, 1960; Surwit, et al., 2009), resulting in an increase in fasting glucose levels. Future research is needed examining the mechanisms by which treatment-related reductions in hostility may translate into favorable metabolic effects.

The small weight losses associated with this citalopram intervention appeared to have had a more widespread influence on metabolic risk than the effects of hostility change per se. The finding that weight loss may partially account for the metabolic effects of SSRIs is at odds with some of the previous research in this area, which suggested that short term metabolic changes associated with SSRI treatment were independent of weight loss (Breum, et al., 1995; Maheux, et al., 1997); this difference may be attributed to the larger sample used here, with associated increases in power to detect relatively small drug-related changes in weight, as well as to differences in the type of drug (fluoxetine vs. citalopram) used in these investigations.
We were unable to characterize the mechanisms explaining the observed effects of citalopram on weight loss and associated metabolic changes in this study; as noted, neither diet, physical activity, nor alcohol consumption appeared to be altered by the intervention in a manner that might explain these results. It is possible that the drugs were associated with small direct changes in metabolic activity which drove the weight loss; alternatively, it is possible that the three measures of health behavior used here were not sensitive enough to detect the rather small changes in behavior which would have been necessary to cause the observed alterations in weight.

An important question about the current metabolic results involves the extent to which they are clinically significant. The effects of the drug on metabolic risk factors did appear to be rather small; it is of interest, however, that the sample was actually much healthier at baseline than many of those previously enrolled in studies of SSRIs and metabolic change. For example, diabetics were excluded by design. It is possible that the relatively small effects are attributable to the health of the sample, and that larger effects might be observed among higher risk groups.

A second related question concerns the extent to which the effects observed here may be sustained over time. Previous work suggests that the initially observed beneficial effects of SSRIs, such as fluoxetine, on body mass index are transient (Michelson, et al., 1999; Ward, Comer, Haney, Fischman, & Foltin, 1999). Indeed, clinical trials comparing nefazodone with SSRIs have shown that many of the latter agents, although associated with acute decreases
in weight, are linked with significant weight gain with long term treatment relative to the comparison group (Sussman, Ginsberg, & Bikoff, 2001). There is even some nonexperimental evidence linking long term use of SSRIs with increased risk for the metabolic syndrome (Raeder, Bjelland, Emil, & Steen, 2006) or for diabetes (Andersohn, Schade, Suissa, & Garbe, 2009), although in both cases, there is some heterogeneity of findings across different agents, with no detectable deleterious metabolic effects associated with use of citalopram per se (Andersohn, et al., 2009; Raeder, et al., 2006). There is some evidence that down regulation of serotonergic autoreceptors with chronic treatment may play a role in the reversal of appetite or weight suppression effects associated with SSRIs (Harvey & Bouwer, 2000). In any case, these results would appear to limit the generalizability of the current set of findings to chronic treatment. Clearly, more remains to be understood about the relationship between SSRI use, body weight, and metabolic risk.

A third question about these data that deserves further investigation involves the implications of these effects for future intervention efforts. The present study, as an experimental manipulation of hostility, would seem to present an opportunity to rule out third factor explanations of the previously observed associations between hostility and metabolic risk. The manipulation chosen here, however, appeared to have pleotropic effects (weight changes) that were not specific to hostility per se. Testing the relationship between hostility and metabolic risk in the context of behaviorally based methods of anger management might be an important means of cross validating the current study.
as an experimental test of the effects of hostility on metabolic risk unconfounded by the impact of weight loss. Of interest, previous behavioral interventions for hostility reduction have been shown to have some effects on resting blood pressure (Gidron, Davidson, & Bata, 1999) and not on measures of heart rate variability (Sloan, et al., 2010). No other metabolic outcomes have been explored in such studies, to our knowledge. This may be a potentially productive area for future research.

In summary, we have shown that short term pharmacologic enhancement of serotonergic function appears to improve both psychosocial and metabolic markers of cardiovascular risk in a high hostile sample. The results of this study have implications for beginning to understand the mechanisms by which hostility may cluster with risk factors for heart disease and, by extension, some of the pathways by which hostility may be linked with cardiovascular endpoints. These results may also have implications for intervention, suggesting that short term augmentation in central serotonergic function more generally, and reductions in hostile affect specifically may have small but significant benefits in individuals with psychosocial risk factors for CVD. Future research is needed to explore the mechanisms accounting for these results, and the generalizability of these findings, across populations, across time, and across intervention modality.
Footnotes

1 For more information on screening procedures, see (Kamarck, et al., 2009).

2 Two subjects in the active drug group showed weight losses greater than 3 standard deviations beyond the mean for the group, and one subject in the control group showed weight gains greater than 3 standard deviations beyond the group mean.

3 Data reduction procedures, factor patterns, and factor scores are identical to those described in the original paper (Kamarck, et al., 2009). The three major factors (Hostile Affect, Hostile Behavior, and Hostile Cognition) were scored based upon unit-weighted averages of the standard (z) scores associated with each of the highly loading component subscales. Because the internal reliabilities of the original BDHI subscales were quite low, these were subjected to an initial data reduction prior to their inclusion in the omnibus model.
Acknowledgements

The authors are grateful to the individuals who participated in this study. We also thank Barbara Anderson, Mary Witzig, Todd Bear, Melissa Delaney, and Lisa Tamres for their assistance with data collection, and Teresa Steigerwalt, HJ Decker, and Rachel Mackey for their assistance with data management. Some of these data were presented previously at the 2008 Annual Meeting of the American Psychosomatic Society in Baltimore, Maryland.
References


Figure Captions

*Figure 1.* Recruitment flowchart.

*Figure 2.* Treatment effects on metabolic risk factors
Figure 1. Recruitment flowchart.
Figure 2. Treatment Effects on Metabolic Risk Factors

- **Signif within-group change**
- **Signif condition-by-time interaction**
Table 1

Baseline Measures of Metabolic Risk Factors, by Condition and Sex

<table>
<thead>
<tr>
<th></th>
<th>Active Drug Condition</th>
<th>Placebo Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=42 men, 39 women</td>
<td>n=37 men, 41 women</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>29.2 (5.0)</td>
<td>28.9 (4.2)</td>
</tr>
<tr>
<td>Women</td>
<td>31.1 (5.6)</td>
<td>28.9 (7.3)</td>
</tr>
<tr>
<td>Waist Circumference (cm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>98.7 (11.9)</td>
<td>99.6 (13.1)</td>
</tr>
<tr>
<td>Women</td>
<td>96.0 (14.3)</td>
<td>91.7 (17.5)</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>41.6 (9.4)</td>
<td>43.1 (8.2)</td>
</tr>
<tr>
<td>Women</td>
<td>51.2 (10.1)</td>
<td>53.4 (12.1)</td>
</tr>
<tr>
<td>Triglycerides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>152.4 (108.1)</td>
<td>150.6 (98.4)</td>
</tr>
<tr>
<td>Women</td>
<td>144.4 (145.9)</td>
<td>116.9 (67.2)</td>
</tr>
<tr>
<td>Glucose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>96.5 (12.2)</td>
<td>95.3 (7.9)</td>
</tr>
<tr>
<td>Women</td>
<td>93.4 (13.0)</td>
<td>92.3 (10.9)</td>
</tr>
<tr>
<td>Insulin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Men | 15.9 (14.3) | 12.8 (6.7)  
Women | 17.4 (17.8) | 14.1 (9.5)  

**Blood Pressure (Manual)**

**SBP**

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>109.3 (8.0)</td>
<td>110.9 (9.2)</td>
</tr>
<tr>
<td>Women</td>
<td>106.4 (9.2)</td>
<td>106.4 (8.9)</td>
</tr>
</tbody>
</table>

**DBP**

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>75.9 (6.1)</td>
<td>77.3 (8.8)</td>
</tr>
<tr>
<td>Women</td>
<td>74.1 (8.3)</td>
<td>74.7 (7.5)</td>
</tr>
</tbody>
</table>

**Blood Pressure (Automated)**

**SBP**

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>116.9 (8.6) 5</td>
<td>116.0 (9.9)</td>
</tr>
<tr>
<td>Women</td>
<td>107.8 (11.7) 5</td>
<td>109.4 (12.7)</td>
</tr>
</tbody>
</table>

**DBP**

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>74.9 (6.3) 5</td>
<td>73.8 (7.5)</td>
</tr>
<tr>
<td>Women</td>
<td>70.1 (8.3) 5</td>
<td>70.7 (7.8)</td>
</tr>
</tbody>
</table>

---

*Note.* Scores are displayed as $M (std)$. 1\textsuperscript{n}=39, 2\textsuperscript{n}=33, 3\textsuperscript{n}=35, 4\textsuperscript{n}=36, 5\textsuperscript{n}=41.